Joint Inspections and Parallel Scientific Advice: Same Weaknesses?

The EU and the US regulatory bodies will have to work hard if their planned joint inspections pilot programme is to be more successful than their efforts to provide joint parallel scientific advice, says Fabien Roy.

Fabien Roy is a legal assistant at the Brussels office of law firm Hogan & Hartson. E-mail: froy@hhlaw.com.

Along with the scientific uncertainty inherent in developing new drugs, companies seeking international approval for their products must deal with an additional worry: navigating the diverse regulatory systems around the...

More from Archive

More from Pink Sheet